STOP WASHINGTON FROM IMPOSING FLAWED PRICING SCHEMES
The United States is in a new era of medical discovery that holds unlimited promise for potential medicines targeting complex conditions, like Alzheimer’s and cancer. Unfortunately, some in Washington are willing to throw all of that progress away. They want to give the government unprecedented power to import flawed pricing policies from other countries that restrict access to innovative medicines. Tell Washington we do not need to put medical innovation in jeopardy to make medicines more affordable.
MAKE YOUR VOICE HEARD
Are you a champion for innovation?
Are you a champion for innovation?
Today’s advancements in personalized medicines and breakthrough treatments are changing lives and providing hope to patients. But some in Washington, DC, have suggested policy changes that would jeopardize investment in science and the very breakthroughs that American patients rely on.
Important conversations are also happening to help ensure Americans have affordable access to their medicines. As policymakers debate changes to the health care system, we must advocate for proposals that not only help people access their medicines but also support the development of the next generation of treatments and cures that have the potential to save lives.
Tell Washington not to threaten future medical innovation with flawed international reference pricing schemes.
We need public policies that take into account the investment and time needed to develop life-saving treatments and cures. The Department of Health and Human Services is currently considering drastic changes to Medicare that would put research and development (R&D) at risk. The proposal, known as the International Pricing Index (IPI) model, would set U.S. prices for medicines covered under Medicare Part B based on prices mandated by 14 foreign governments. This concept - called reference pricing - is one of many harmful policies other countries use that undervalue innovation and have contributed to less investment in R&D. And the IPI model would put at risk the development of innovative medicines for some cancers and potential cures for genetic disorders. In fact, 70 percent of biopharmaceutical companies surveyed expected significant cuts in cancer R&D if the IPI model is implemented. We need supportive policies to sustain innovation that patients rely on, not policies like the IPI that discourage continued medical innovation here in the United States.
Tell lawmakers to protect innovation when addressing health care costs.
Voters for Cures
The next medical breakthrough is more than just science. It’s personal. Voters for Cures is a leading voice for patients, their families and the health care professionals who understand what’s at stake if policies do not support patient affordability and access, as well as continued medical innovation. Our efforts focus on three core areas:
The following articles share policy solutions, exciting R&D progress, and advocate spotlights where patients and those that care for them share the reasons why they vote for cures.
Over the years, treatments for infectious diseases have grown steadily more complex, and today, our ability to respond to diseases like COVID-19 is radically different than it would have been even a few decades ago.READ MORE
As people across the globe continue to be impacted by COVID-19, the disease caused by a new strain of coronavirus, biopharmaceutical companies have rapidly taken action to research and develop potential new medicines, while partnering with public health leaders worldwide, to combat this global public health emergency.READ MORE
HELP PROTECT THE FUTURE OF MEDICINE
Innovation is headed to your inbox.
Sign up to learn how you can help protect breakthroughs today.